This company listing is no longer active
ISR Stock Overview
ISR Immune System Regulation Holding AB (publ) develops immunostimulatory drugs to treat chronic infectious diseases and cancer in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ISR Immune System Regulation Holding AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.40 |
| 52 Week High | SEK 8.60 |
| 52 Week Low | SEK 1.19 |
| Beta | 0.45 |
| 11 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | -74.45% |
| 33 Year Change | -50.70% |
| 5 Year Change | -86.21% |
| Change since IPO | -86.98% |
Recent News & Updates
Recent updates
We're Not Very Worried About ISR Immune System Regulation Holding's (STO:ISR) Cash Burn Rate
Aug 11
A Look At The Fair Value Of ISR Immune System Regulation Holding AB (publ) (STO:ISR)
Jul 02Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Mar 08Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Nov 18Is ISR Immune System Regulation Holding (STO:ISR) In A Good Position To Deliver On Growth Plans?
Jul 27Here's Why We're Watching ISR Immune System Regulation Holding's (STO:ISR) Cash Burn Situation
Mar 26We Think ISR Immune System Regulation Holding (STO:ISR) Can Afford To Drive Business Growth
Dec 11
Shareholder Returns
| ISR | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0% | 1.3% | 1.5% |
| 1Y | -74.5% | 11.3% | 14.0% |
Return vs Industry: ISR underperformed the Swedish Biotechs industry which returned 4% over the past year.
Return vs Market: ISR underperformed the Swedish Market which returned -6.8% over the past year.
Price Volatility
| ISR volatility | |
|---|---|
| ISR Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: ISR's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine ISR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 5 | Ola Winqvist | israb.se |
ISR Immune System Regulation Holding AB (publ) develops immunostimulatory drugs to treat chronic infectious diseases and cancer in Sweden. Its product pipeline includes Covid-19 vaccine, hepatitis B (HBV), human immunodeficiency virus (HIV), and oncology drugs. The company was founded in 2007 and is headquartered in Solna, Sweden.
ISR Immune System Regulation Holding AB (publ) Fundamentals Summary
| ISR fundamental statistics | |
|---|---|
| Market cap | SEK 96.61m |
| Earnings (TTM) | -SEK 213.05m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.5x
P/E RatioIs ISR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ISR income statement (TTM) | |
|---|---|
| Revenue | SEK 0 |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 0 |
| Other Expenses | SEK 213.05m |
| Earnings | -SEK 213.05m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.09 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -0.6% |
How did ISR perform over the long term?
See historical performance and comparison